Co-targeting these kinases is a rational approach to break tumor cell tolerance, either by using inhibitors with a wilder specificity (e.g., afatinib) or a combination of inhibitors (e.g., EGFR TKI plus crizotinib). The gene discussed is EGFR; the disease is neoplasm.